-
Je něco špatně v tomto záznamu ?
The effect of left atrial appendage closure on heart failure biomarkers: A PRAGUE-17 trial subanalysis
D. Herman, P. Osmancik, P. Neuzil, P. Hala, V. Lekesova, K. Benesova, M. Hozman, J. Jarkovsky, M. Novackova, P. Widimsky, VY. Reddy, PRAGUE-17 Trial Investigators
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem
NLK
CINAHL Plus with Full Text (EBSCOhost)
od 1990-02-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 1990-02-01 do Před 1 rokem
PubMed
34402135
DOI
10.1111/jce.15206
Knihovny.cz E-zdroje
- MeSH
- antikoagulancia terapeutické užití MeSH
- aplikace orální MeSH
- biologické markery MeSH
- cévní mozková příhoda * MeSH
- fibrilace síní * diagnóza farmakoterapie chirurgie MeSH
- lidé MeSH
- síňové ouško * diagnostické zobrazování chirurgie MeSH
- srdeční selhání * diagnóza farmakoterapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
INTRODUCTION: The randomized PRAGUE-17 trial demonstrated noninferiority of left atrial appendage closure (LAAC) to non-vitamin K anticoagulants (NOACs) for the prevention of major cardiovascular or cerebrovascular events. However, the left atrial appendage is an important source of natriuretic peptides and plays a role in left atrial reservoir function. Changes of heart failure (HF) biomarkers after LAAC compared to NOAC has not been studied. The aim of the study was to compare the changes in concentrations of HF biomarkers between LAAC and NOAC patients. METHODS: Of 402 patients randomized in the PRAGUE-17 trial, biomarkers were analyzed in 144 patients (73 in the NOAC and 71 in the LAAC group). Both groups had similar baseline characteristics. Serum concentration of NT-proBNP, NT-proANP, Galectin-3, and GDF-15 were measured at baseline (before the procedure in the LAAC group), at the 6-month (and at 24-month for NT-proBNP) follow-up timepoint. RESULTS: There were no significant differences in baseline, 6 month, and delta (δ = baseline - 6 month) concentrations of NT-proANP between the groups (NOAC: baseline 2.6 [0.5; 4.9], 6-month 3.1 [1.8; 4.8], p = .068; LAAC: baseline 3.3 [1.1; 4.6], 6-month 2.6 [0.9; 5.3], p = .51; p value for δ in concentrations between groups = 0.42). Similarly, there were no significant differences in baseline, 6, 24 months, and delta concentrations of NT-proBNP between the groups (NOAC: baseline 461.0 [113.5; 1342.0], 6 month 440.0 [120.5; 1291.5], 24 month 798 [274; 2236], p = .39; LAAC: baseline 421.0 [100.0; 1320.0], 6 month 601.0 [145.0; 1230.0], 24 month 855 [410; 1367], p = .28; p value for δ in concentrations between groups = 0.73 at 6 months, and 0.58 at 24 months). Finally, no significant differences were present in baseline, 6 month, and δ concentrations of Galectin-3 and GDF-15 between the two groups. CONCLUSION: LAAC did not significantly influence the levels of HF biomarkers 6 months after the procedure.
Cardiocenter Department of Cardiology Na Homolce Hospital Prague Czech Republic
Cardiocenter Karlovy Vary Regional Hospital Karlovy Vary Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22003599
- 003
- CZ-PrNML
- 005
- 20220127150053.0
- 007
- ta
- 008
- 220113s2021 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/jce.15206 $2 doi
- 035 __
- $a (PubMed)34402135
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Herman, Dalibor $u Department of Cardiology, Third Faculty of Medicine, University Hospital Kralovske Vinohrady, Charles University Prague, Prague, Czech Republic
- 245 14
- $a The effect of left atrial appendage closure on heart failure biomarkers: A PRAGUE-17 trial subanalysis / $c D. Herman, P. Osmancik, P. Neuzil, P. Hala, V. Lekesova, K. Benesova, M. Hozman, J. Jarkovsky, M. Novackova, P. Widimsky, VY. Reddy, PRAGUE-17 Trial Investigators
- 520 9_
- $a INTRODUCTION: The randomized PRAGUE-17 trial demonstrated noninferiority of left atrial appendage closure (LAAC) to non-vitamin K anticoagulants (NOACs) for the prevention of major cardiovascular or cerebrovascular events. However, the left atrial appendage is an important source of natriuretic peptides and plays a role in left atrial reservoir function. Changes of heart failure (HF) biomarkers after LAAC compared to NOAC has not been studied. The aim of the study was to compare the changes in concentrations of HF biomarkers between LAAC and NOAC patients. METHODS: Of 402 patients randomized in the PRAGUE-17 trial, biomarkers were analyzed in 144 patients (73 in the NOAC and 71 in the LAAC group). Both groups had similar baseline characteristics. Serum concentration of NT-proBNP, NT-proANP, Galectin-3, and GDF-15 were measured at baseline (before the procedure in the LAAC group), at the 6-month (and at 24-month for NT-proBNP) follow-up timepoint. RESULTS: There were no significant differences in baseline, 6 month, and delta (δ = baseline - 6 month) concentrations of NT-proANP between the groups (NOAC: baseline 2.6 [0.5; 4.9], 6-month 3.1 [1.8; 4.8], p = .068; LAAC: baseline 3.3 [1.1; 4.6], 6-month 2.6 [0.9; 5.3], p = .51; p value for δ in concentrations between groups = 0.42). Similarly, there were no significant differences in baseline, 6, 24 months, and delta concentrations of NT-proBNP between the groups (NOAC: baseline 461.0 [113.5; 1342.0], 6 month 440.0 [120.5; 1291.5], 24 month 798 [274; 2236], p = .39; LAAC: baseline 421.0 [100.0; 1320.0], 6 month 601.0 [145.0; 1230.0], 24 month 855 [410; 1367], p = .28; p value for δ in concentrations between groups = 0.73 at 6 months, and 0.58 at 24 months). Finally, no significant differences were present in baseline, 6 month, and δ concentrations of Galectin-3 and GDF-15 between the two groups. CONCLUSION: LAAC did not significantly influence the levels of HF biomarkers 6 months after the procedure.
- 650 _2
- $a aplikace orální $7 D000284
- 650 _2
- $a antikoagulancia $x terapeutické užití $7 D000925
- 650 12
- $a síňové ouško $x diagnostické zobrazování $x chirurgie $7 D020517
- 650 12
- $a fibrilace síní $x diagnóza $x farmakoterapie $x chirurgie $7 D001281
- 650 _2
- $a biologické markery $7 D015415
- 650 12
- $a srdeční selhání $x diagnóza $x farmakoterapie $7 D006333
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a cévní mozková příhoda $7 D020521
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Osmancik, Pavel $u Department of Cardiology, Third Faculty of Medicine, University Hospital Kralovske Vinohrady, Charles University Prague, Prague, Czech Republic
- 700 1_
- $a Neuzil, Petr $u Cardiocenter, Department of Cardiology, Na Homolce Hospital, Prague, Czech Republic
- 700 1_
- $a Hala, Pavel $u Cardiocenter, Department of Cardiology, Na Homolce Hospital, Prague, Czech Republic
- 700 1_
- $a Lekesova, Veronika $u Cardiocenter, Department of Cardiology, Na Homolce Hospital, Prague, Czech Republic
- 700 1_
- $a Benesova, Klara $u Department of Data Analysis, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Hozman, Marek $u Cardiocenter, Karlovy Vary Regional Hospital, Karlovy Vary, Czech Republic
- 700 1_
- $a Jarkovsky, Jiri $u Department of Data Analysis, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Novackova, Martina $u Department of Data Analysis, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Widimsky, Petr $u Department of Cardiology, Third Faculty of Medicine, University Hospital Kralovske Vinohrady, Charles University Prague, Prague, Czech Republic
- 700 1_
- $a Reddy, Vivek Y $u Cardiocenter, Department of Cardiology, Na Homolce Hospital, Prague, Czech Republic $u Department of Electrophysiology, Helmsley Electrophysiology Center, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- 710 2_
- $a PRAGUE-17 Trial Investigators
- 773 0_
- $w MED00002569 $t Journal of cardiovascular electrophysiology $x 1540-8167 $g Roč. 32, č. 10 (2021), s. 2645-2654
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34402135 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220113 $b ABA008
- 991 __
- $a 20220127150050 $b ABA008
- 999 __
- $a ok $b bmc $g 1751153 $s 1154748
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 32 $c 10 $d 2645-2654 $e 20210826 $i 1540-8167 $m Journal of cardiovascular electrophysiology $n J Cardiovasc Electrophysiol $x MED00002569
- LZP __
- $a Pubmed-20220113